首站-论文投稿智能助手
典型文献
Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism
文献摘要:
The limited treatment options for advanced prostate cancer(PCa)lead to the urgent need to discover new anticancer drugs.Mannose,an isomer of glucose,has been reported to have an anticancer effect on various tumors.However,the anticancer effect of mannose in PCa remains unclear.In this study,we demonstrated that mannose inhibits the proliferation and promotes the apoptosis of PCa cells in vitro,and mannose was observed to have an anticancer effect in mice without harming their health.Accumulation of intracellular mannose simultaneously decreased the mitochondrial membrane potential,increased mitochondrial and cellular reactive oxygen species(ROS)levels,and reduced adenosine triphosphate(ATP)production in PCa cells.Mannose treatment of PCa cells induced changes in mitochondrial morphology,caused dysregulated expression of the fission protein,such as fission,mitochondrial 1(FIS1),and enhanced the expression of proapoptotic factors,such as BCL2-associated X(Bax)and BCL2-antagonist/killer 1(Bak).Furthermore,lower expression of mannose phosphate isomerase(MPI),the key enzyme in mannose metabolism,indicated poorer prognosis in PCa patients,and downregulation of MPI expression in PCa cells enhanced the anticancer effect of mannose.This study reveals the anticancer effect of mannose in PCa and its clinical significance in PCa patients.
文献关键词:
作者姓名:
Yu-Lin Deng;Ren Liu;Zhou-Da Cai;Zhao-Dong Han;Yuan-Fa Feng;Shang-Hua Cai;Qing-Biao Chen;Jian-Guo Zhu;Wei-De Zhong
作者机构:
Guangdong Provincial Institute of Nephrology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Andrology,Guangzhou First People's Hospital,School of Medicine,South China University of Technology,Guangzhou 510180,China;Department of Urology,Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics,Guangzhou First People's Hospital,School of Medicine,South China University of Technology,Guangzhou 510180,China;Urology Key Laboratory of Guangdong Province,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou Medical University,Guangzhou 510230,China;Department of Urology Surgery,Affiliated Foshan Hospital of Southern Medical University,Foshan 528000,China;Department of Urology,Guizhou Provincial People's Hospital,The Affiliated Hospital of Guizhou Medical University,Guiyang 550002,China
引用格式:
[1]Yu-Lin Deng;Ren Liu;Zhou-Da Cai;Zhao-Dong Han;Yuan-Fa Feng;Shang-Hua Cai;Qing-Biao Chen;Jian-Guo Zhu;Wei-De Zhong-.Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism)[J].亚洲男性学杂志(英文版),2022(05):540-548
A类:
Mannose
B类:
inhibits,growth,prostate,through,mitochondrial,mechanism,limited,treatment,options,advanced,PCa,lead,urgent,need,discover,new,anticancer,drugs,glucose,has,been,reported,have,effect,various,tumors,However,mannose,remains,unclear,In,this,study,demonstrated,that,proliferation,promotes,apoptosis,cells,vitro,was,observed,mice,without,harming,their,health,Accumulation,intracellular,simultaneously,decreased,membrane,potential,increased,reactive,oxygen,species,ROS,levels,reduced,adenosine,triphosphate,ATP,production,induced,changes,morphology,caused,dysregulated,expression,fission,protein,such,FIS1,enhanced,proapoptotic,factors,BCL2,associated,Bax,antagonist,killer,Bak,Furthermore,lower,isomerase,MPI,key,enzyme,metabolism,indicated,poorer,prognosis,patients,downregulation,This,reveals,clinical,significance
AB值:
0.529906
相似文献
Spirulina platensis aqueous extracts ameliorate colonic mucosal damage and modulate gut microbiota disorder in mice with ulcerative colitis by inhibiting inflammation and oxidative stress
Jian WANG;Liqian SU;Lun ZHANG;Jiali ZENG;Qingru CHEN;Rui DENG;Ziyan WANG;Weidong KUANG;Xiaobao JIN;Shuiqing GUI;Yinghua XU;Xuemei LU-Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances,School of Life Science and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510006,China;School of Pharmacy,Guangdong Pharmaceutical University,Guangzhou 510006,China;Intensive Care Unit,Shenzhen Second People's Hospital,the First Affiliated Hospital of Shenzhen University,Shenzhen 518031,China;Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,National Institutes for Food and Drug Control,Beijing 102629,China
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma
Jingrong Xian;Shiwen Wang;Yanyu Jiang;Lihui Li;Lili Cai;Ping Chen;Yue Liu;Xiaofei Zeng;Guoan Chen;Chen Ding;Robert M.Hoffman;Lijun Jia;Hu Zhao;Yanmei Zhang-Department of Laboratory Medicine,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Research Center on Aging and Medicine,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China;Department of Basic Science of Oncology,College of Basic Medical Sciences,Zhengzhou University,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;School of Medicine,Southern University of Science and Technology,Shenzhen 518055,China;State Key Laboratory of Genetic Engineering,Human Phenome Institute,Institutes of Biomedical Sciences,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200032,China;State Key Laboratory of Cell Differentiation and Regulation,Henan International Joint Laboratory of Pulmonary Fibrosis,Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis,College of Life Science,Institute of Biomedical Science,Henan Normal University,Xinxiang 453007,China;Department of Surgery,University of California,San Diego 92101,USA;Anticancer Inc.,San Diego 92101,USA
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
Qiong Wang;Zean Li;Jin Yang;Shirong Peng;Qianghua Zhou;Kai Yao;Wenli Cai;Zhongqiu Xie;Fujun Qin;Hui Li;Xu Chen;Kaiwen Li;Hai Huang-Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Pathology,School of Medicine,University of Virginia,Charlottesville,VA 22908,USA;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Radiation Oncology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Urology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Department of Radiology,Massachusetts General Hospital,Harvard Medical School,Boston,MA 02114,USA;Department of Urology,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China
Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy
Huan Xu;Junyi Chen;Zhi Cao;Xi Chen;Caihong Huang;Jin Ji;Yalong Xu;Junfeng Jiang;Yue Wang;Guowang Xu;Lina Zhou;Jingyi He;Xuedong Wei;Jason Boyang Wu;Zhong Wang;Shancheng Ren;Fubo Wang-Department of Urology,Shanghai Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Department of Urology,Shanghai Ninth People's Hospital,Shanghai 200011,China;Department of Urology,the Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;Department of Urology,No.971 Hospital of the People's Liberation Army Navy,Qingdao 266000,China;Center for Genomic and Personalized Medicine,Guangxi Key Laboratory for Genomic and Personalized Medicine,Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine,Guangxi Medical University,Nanning 530021,China;Research Center of Developmental Biology,Second Military Medical University,Shanghai 200433,China;Dalian Institute of Chemical Physics,Chinese Academy of Sciences,Dalian 116023,China;Department of Urology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China;Department of Pharmaceutical Sciences,College of Pharmacy and Pharmaceutical Sciences,Washington State University,Spokane,WA 99202,USA
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。